ANZCTR search results

Chemotherapy can improve both the length and qualtiy of life in women with advanced breast cancer, however the best approach is unclear for women unsuited to intensive chemotherapy. This randomised trial aims to find out whether simple daily oral chemotherapy (Capecitabine) or standard chemotherapy including injections (CMF) is best for such women. The study looks at the effects of disease and treatment on both length and quality of life.

The study has been designed around the research questions a) do patients with chronic respiratory disease (asthma and/or COPD) managed with lung function testing (spirometry) through general practice have better health outcomes than patients managed without spirometry? and b) to what degree does the use of spirometry influence the way general practitioners manage patients with chronic respiratory disease? This study aims to trial lung function testing ( spirometry) as an intervention for management of asthma and chronic obstructive pulmonary disease ( COPD) in a General practice setting. The main objectives are a) to evaluate the impact of spirometry on health outcomes of patients with asthma and COPD,compared with usual care alone ( no spirometry) and b) to identify the barriers and enablers to spirometry in general practice and primary care.

Investigator initiated separate sub-study to the VYTUL study to measure novel serum biomarkers associated with increased heart disease risk to ascertain whether these biomarkers are predictive of response in this population and whether further work on targeting these biomarkers is warranted. A second part to the substudy will focus on exploring non-physiological external factors that may contribute to ineffective risk factor modification and ultimately increased CHD risk in this population.

Study Hypothesis: We hypothesise that participants receiving the subvastus approach will enjoy better medium term funtional outcomes than those receiving the medial parapatell approach. Physiotherapists are blinded to the intervention and will collect all outcome measures at each assessment point. Participants are blinded to the intervention.

The trial assessed the effect of different oxgen saturation targeting ranges on the long-term growth and development of oxygen-dependent, extremely preterm infants.

To determine if the introduction of Vytorin will be more effective than increasing the dose of Atorvastain in achieving LDL ('bad cholesterol') and other cholesterol level goals in high risk patients who have been treated for at least the last three months with atorvastatin 40 mg and still have uncontrolled cholesterol levels.

Patients with relapsed or refractory lymphoma require initial salvage chemotherapy to control their disease. One type of salvage chemotherapy is Rituximab, Ifosfamide and Etoposide (R-IE) given for six cycles administered every 21 days, followed by two additional doses of Rituximab at intervals of 21 days. Ifosfamide and Etopside are given on days 1 to 3 and Rituximab is given on day 1. On the day following each cycle of the R-IE therapy (day 4) a single injection under the skin of pegfilgrastim is given to prevent the white blood cell count from falling too low and therefore reduce the number of infections the patient may experience.

The ProTaT trial is a phase II trial evaluating the safety and activity of the combination of docetaxel (Taxotere), prednisone and Thalidomide in men with metastatic hormone refractory prostae cancer. The hypothesis is that the combination of a standard systemic therapy, docetaxel, with and antiangiogenic agent may improve the response rate in patients with this disease.

Heart disease is Australia's biggest health problem, affecting nearly 3.7 million people every year. Recent research has shown that emotional problems such as depression can make heart problems worse. However, it is often difficult to diagnose depression in people with heart problems. This research aims to improve the general health and wellbeing of people with chronic heart problems and depression by determining whether a special general practitioner enhanced education program, comprising the monitoring of depression, academic detailing of best-practice guidelines and psychiatric advice to the treating GP, will reduce depression in people with chronic heart probalems.

This trial will determine the safety and activity of giving two new drugs together in women with advanced breast cancer. Both of these drugs are active when given alone; giving them together may be better.